Anavex Life Sciences Corp (AVXL)

[Investor2014]

In the recent BTIG conference Missling explained the size of the PDD data to be analysed for peer review and submission to the FDA is time consuming and being performed free of any bias of where too look across the entire genome combined with all the other data points fed into KEM.

It wasn’t clear exactly when that work is completed and ready to be reported, but it certainly didn’t sound like it was in the past.